NCT02693535 · American Society of Clinical Oncology
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
(TAPUR)
What this study is about
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the treatment group$1 section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.
View original scientific description
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
Interventions
DRUG
Palbociclib
drug
DRUG
Sunitinib
drug
DRUG
Temsirolimus
drug
DRUG
Trastuzumab and Pertuzumab
drug
DRUG
Vemurafenib and Cobimetinib
drug
DRUG
Regorafenib
drug
DRUG
Olaparib
drug
DRUG
Nivolumab and Ipilimumab
drug
DRUG
Abemaciclib
drug
DRUG
Talazoparib
drug
DRUG
Atezolizumab and Talazoparib
drug
DRUG
Tucatinib plus Trastuzumab Subcutaneous (SC)
drug
DRUG
Futibatinib
drug
DRUG
Dabrafenib plus Trametinib
Drug
DRUG
Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Drug
Primary outcome measures
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Time frame: Assessed at 16 weeks of treatment
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- 12 years of age or older (\*Restrictions apply. Not all therapies are available for patients \<18)
- Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
- Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
- Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/
Exclusion criteria
- specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria: 1. Absolute neutrophil count ≥ 1.5 x 106/µl 2. Hemoglobin \> 9.0 g/dl 3. Platelets \> 75,000/µl 4. Total bilirubin \< 2.0 mg/ dl, except in patients with Gilbert's Syndrome 5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alani
Where
- Birmingham, Alabama
- Phoenix, Arizona
- Auburn, California
- Berkeley, California
- Los Angeles, California
- Oakland, California
- Palo Alto, California
- Roseville, California
- Sacramento, California
- San Francisco, California
- San Jose, California
- San Leandro, California
And 128 more locations — see the full list below.
Collaborators
AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Pfizer, Taiho Oncology, Inc., Novartis, Merck Institute for Therapeutic Research, Boehringer Ingelheim, Seattle Genetics (now a wholly owned subsidiary of Pfizer)
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced May 29, 2026 · Source of record for eligibility and locations